Literature DB >> 29154961

Inhibition of Cyclooxygenase-2 Suppresses the Recruitment of Endothelial Progenitor Cells in the Microvasculature of Endometriotic Lesions.

Jeannette Rudzitis-Auth1, Ruth M Nickels2, Michael D Menger2, Matthias W Laschke2.   

Abstract

The incorporation of endothelial progenitor cells (EPCs) into newly developing blood vessels contributes to the vascularization of endometriotic lesions. We analyzed whether cyclooxygenase (COX)-2 signaling regulates this vasculogenic process. Endometriotic lesions were surgically induced in irradiated FVB/N mice, which were reconstituted with bone marrow from FVB/N-TgN [Tie2/green fluorescent protein (GFP)] 287 Sato mice. The animals received β-estradiol 17-valerate once a week and were treated daily with the selective COX-2 inhibitor parecoxib (25 mg/kg) or vehicle (control) for 7 and 28 days. Analyses involved the determination of lesion growth, cyst formation, homing of GFP+/Tie2+ EPCs, numbers of circulating EPCs, vascularization, cell proliferation, apoptosis, and immune cell infiltration by means of high-resolution ultrasonography, caliper measurements, flow cytometry, histologic analysis, and immunohistochemical analysis. In parecoxib-treated mice, blood circulating EPCs were higher, but numbers of recruited EPCs in endometriotic lesions were significantly lower when compared with controls. This finding was associated with an impaired early vascularization and stromal tissue growth as well as reduced glandular secretory activity of the lesions. Parecoxib-treated lesions further contained less proliferating and more apoptotic cells and exhibited lower numbers of infiltrating macrophages and neutrophilic granulocytes. These findings demonstrate that the inhibition of COX-2 suppresses vasculogenesis in endometriotic lesions, which may contribute to an impaired lesion vascularization and growth.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29154961     DOI: 10.1016/j.ajpath.2017.10.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

1.  Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signalling suppresses the vascularisation and growth of endometriotic lesions.

Authors:  Jeannette Rudzitis-Auth; Sophia A Fuß; Vivien Becker; Michael D Menger; Matthias W Laschke
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

2.  Hemodynamic forces enhance decidualization via endothelial-derived prostaglandin E2 and prostacyclin in a microfluidic model of the human endometrium.

Authors:  Juan S Gnecco; Tianbing Ding; Caroline Smith; Jacky Lu; Kaylon L Bruner-Tran; Kevin G Osteen
Journal:  Hum Reprod       Date:  2019-04-01       Impact factor: 6.918

Review 3.  New therapeutic approaches for endometriosis besides hormonal therapy.

Authors:  Fang-Ying Chen; Xi Wang; Rui-Yi Tang; Zai-Xin Guo; Yu-Zhou-Jia Deng; Qi Yu
Journal:  Chin Med J (Engl)       Date:  2019-12-20       Impact factor: 2.628

4.  Hypoxia-hindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16- NK-cell differentiation.

Authors:  Haiyan Peng; Lichun Weng; Shating Lei; Shuhui Hou; Shaoliang Yang; Mingqing Li; Dong Zhao
Journal:  Exp Mol Med       Date:  2022-07-04       Impact factor: 12.153

5.  Photoacoustic imaging for the study of oxygen saturation and total hemoglobin in bone healing and non-union formation.

Authors:  Maximilian M Menger; Christina Körbel; David Bauer; Michelle Bleimehl; Anne L Tobias; Benedikt J Braun; Steven C Herath; Mika F Rollmann; Matthias W Laschke; Michael D Menger; Tina Histing
Journal:  Photoacoustics       Date:  2022-09-27

Review 6.  Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk.

Authors:  Nicola Edwards; Alexander W W Langford-Smith; Fiona L Wilkinson; M Yvonne Alexander
Journal:  Front Med (Lausanne)       Date:  2018-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.